Loading clinical trials...
Loading clinical trials...
A Prospective, Epidemiological Study to Assess the Disease Burden of RSV Associated, Suspected LRTIs From 0 to 2 Years and Population Attributable Risk Percent of RSV LRTI on the Development of Recurrent Wheeze and Asthma From 0 to 6 Years
The purpose of this study is to assess the incidence and associated healthcare utilization of RSV-associated, suspected LRTI in a general population of infants from birth up to 2 years of age, and also to assess the accuracy of a newly developed LRTI case definition and severity scale compared to two existing definitions. The study will also assess the population attributable risk percent of RSV LRTI on the development of wheeze and asthma from 0 to 6 years of age.
New born infants from various countries over the world will be followed up for up to two years for the occurrence of Lower Respiratory Tract Infections. Through active and passive surveillance, any suspected case will be identified, assessed during an examination visit and followed up until completion through a diary card. Full symptomology will be assessed during the examination visit. The disease course and all healthcare utilization will be subsequently collected through a two-week diary card and contact with ay healthcare providers involved in management of the disease. RSV detection will occur through quantitative PCR of collected nasal swabs. A baseline cord blood serum sample of all subjects and a follow-up blood serum sample from a sub-cohort will also be collected to assess antibody levels at various points in time and in relation to risk of RSV LRTI. For extension period, pertaining to wheeze and asthma (Epoch 002): Subjects' parent(s)/LAR(s) will be asked to re-consent and subjects will be followed up through quarterly contacts up to the age of 6 years. Data collection will also occur from medical charts retrospectively for those who have a gap period between the end of the primary study and providing re-consent for the extension. The extension involves enrolment visit (at 2nd birthday \[on completion of primary study or as soon as possible thereafter\]) and quarterly surveillance contacts.
Age
0 - 6 years
Sex
ALL
Healthy Volunteers
Yes
GSK Investigational Site
Oakland, California, United States
GSK Investigational Site
Sacramento, California, United States
GSK Investigational Site
Sacramento, California, United States
GSK Investigational Site
Santa Clara, California, United States
GSK Investigational Site
Walnut Creek, California, United States
GSK Investigational Site
Syracuse, New York, United States
GSK Investigational Site
Roy, Utah, United States
GSK Investigational Site
Syracuse, Utah, United States
GSK Investigational Site
Seattle, Washington, United States
GSK Investigational Site
Ciudad de Buenos Aires, Buenos Aires, Argentina
Start Date
December 12, 2013
Primary Completion Date
October 3, 2017
Completion Date
November 3, 2021
Last Updated
November 29, 2022
2,409
ACTUAL participants
Nasal swab sampling
PROCEDURE
Blood sampling
PROCEDURE
Diary cards
OTHER
Lead Sponsor
GlaxoSmithKline
NCT07220109
NCT07092865
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04959734